• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pops! Diabetes Care raises funds for newly-approved glucose monitoring system

January 4, 2019 By Sarah Faulkner

Pops Diabetes Care logo updatedPops! Diabetes Care said yesterday that it closed a new equity financing round to support the launch of its newly-approved Pops! One blood glucose monitoring system.

The Park Heights, Minn.-based company did not disclose how much money it raised but it did report that 30Ventures led the round.

“We are honored by the support and trust of investors to change diabetes management,” CEO Lonny Stormo said in prepared remarks, “The Pops! team is excited to commercialize our solution and help people with diabetes own their life.”

“We recognized a big opportunity in Pops!, and are very excited to lead this financing and help drive the launch of the Pops! One System. It offers an elegant solution for millions trying to manage their diabetes efficiently, discretely, and effectively,” George Arida, managing director of 30Ventures, added. “The opportunity to see better patient outcomes and make a real cost impact on the most expensive healthcare category in the US – these are two big value drivers that we believe make for a compelling story.”

The company’s device, which won FDA clearance in December, can be attached directly to the back of a mobile phone and interacts with the user through a coaching app. The Pops! One system also allows users to review their blood glucose trends and share the data with family members and healthcare professionals.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup Tagged With: popsdiabetescare

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS